Physician profile
Andrew E Mendians
NPI 1386692218
$1,776.62
in general payments reported to CMS, 2019-2025
12 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Otolaryngology/Facial Plastic Surgery provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,249 · 2020: $76.73 · 2021: $83.86 · 2022: $49.61 · 2023: $18.84 · 2024: $13.76 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $304 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $303.90 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,008.84 | 2019 | |
| Acclarent, INC | $299.17 | 2019-2021 | |
| Integra Lifesciences Corporation | $100.59 | 2025 | Inspira Air, Acclarent Aera, Trudi Probe |
| Aerin Medical INC. | $84.42 | 2023-2025 | |
| Stryker Corporation | $76.73 | 2020 | |
| Genzyme Corporation | $68.83 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.30 | 2024-2025 | Eohilia |
| Regeneron Healthcare Solutions, INC. | $35.87 | 2025 | Dupixent |
| Glaxosmithkline, LLC. | $17.07 | 2025 | Nucala |
| Smith+Nephew, INC. | $14.19 | 2022 | |
| Medtronic USA, INC. | $13.13 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Mendians listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.